apceth Biopharma to Present new data for apceth-201 and apceth-301

apceth Biopharma to Present new data for apceth-201 and apceth-301 at the American Society of Gene and Cell Therapy (ASGCT) 2018 Annual Meeting

apceth Biopharma GmbH, a company with the mission of improving patients’ lives with next generation cell therapies, announced today that it has been selected for 2 oral presentations on apceth-201 and apceth-301 at the American Society of Gene and Cell Therapy (ASGCT) 2018 Annual Meeting that will take place in Chicago on May 16-19, 2018.

  • apceth’s first presentation is titled “Intracerebral Immunomodulation Using Genetically Engineered Mesenchymal Stem Cells Induces Long-Term Survival and Immunity in Glioblastoma” and will be given by Prof. Dr. Nils Ole Schmidt from the University Clinic Hamburg-Eppendorf. Prof. Schmidt will present the latest results regarding apceth-301 which is being developed for the treatment of solid tumors. The presentation will take place on Wednesday May 16 between 11:15 AM – 11:30 AM in Salon A-1/2 (abstract number 22).
  • The second presentation is titled “Human Mesenchymal Stem Cells Genetically Engineered to Express Alpha-1 Anti-Trypsin (apceth-201) Confer a Long-Term Survival Benefit in a Lethal, Haplo-Identical Mouse Model of Graft-Vs-Host-Disease” and will be given by Dr. Ulf Geumann of apceth. The presentation will take place on Thursday May 17 between 5:00PM – 5:15PM in the International Ballroom North (abstract number 351).

“We are honored to have been invited by ASGCT to present the most recent data on apceth-201 and apceth-301”, said Dr. Christine Guenther, CEO of apceth Biopharma. “We are very excited about the data and are currently preparing to move into clinical development.”

About apceth Biopharma GmbH
apceth Biopharma is a pioneering company in cell therapies and regenerative medicine with an innovative portfolio of drug candidates for the treatment of inflammation, autoimmunity and solid cancers. Through introduction of therapeutic transgenes into Mesenchymal Stem Cells (MSCs), apceth is developing two potent next generation MSC-based gene therapy products. apceth-201 expresses the immunomodulatory protein alpha-1 antitrypsin for the treatment of graft-vs-host disease. The company’s second program, apceth-301, expresses a potent immunostimulatory “cocktail” of cytokines which locally activates the immune system to eradicate tumor cells. apceth-301 is currently being developed for glioblastoma as well as for other solid tumors.

apceth is also a leading and certified Contract Development & Manufacturing Organization for Advanced Therapy Medicinal Products (ATMPs) with a broad international and transactlantic customer base. The company has state-of-the-art manufacturing facilities (ISO 5, ISO 7, ISO 8, BSL2 cleanrooms) and is certified according to regulatory requirements for ATMPs. The company has a comprehensive expertise in GMP manufacturing of autologous and allogeneic cell types that are
either native or genetically modified, including mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), lymphocytes, monocytes, dendritic cells, cord blood derived stem cells, and has the potential to expand to CAR-T and induced pluripotent stem cell (iPSCs) technologies. apceth has successfully obtained manufacturing licenses for multiple cell therapy products and provides fully customized solutions in the development and production of every customer product and process. Located centrally in the heart of Europe, apceth can perform efficient and fast supply of the client’s products across the continent.

Download this Pressrelease